FDA for Pfizer vaccine in children: The benefits outweigh the risks

Scientists at the US Food and Drug Administration (FDA) announced yesterday that the potential benefits of administering the Pfizer / BioNTech COVID-19 vaccine to children aged 5 to 11 years clearly outweigh the risks of rare heart attacks.

Earlier yesterday, vaccine companies said their vaccine was 90.7% effective against coronavirus in a clinical trial in children aged 5-11.

The details were included in newsletters released ahead of the panel of independent experts, who are expected to vote on Tuesday on whether to recommend the FDA approve vaccines for this age group.

If the FDA approves the vaccination of children ages 5-11 with Pfizer / BioNTech, it will be the first COVID-19 vaccine for this age group and doses may be available in the US in early November.

Source: ΑΠΕ-ΜΠΕ

Leave a Reply